Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$4.01 -5.6%	$2.82	$1.89 ▼ $4.33	$1.27B	0.62	3.49 million shs	5.62 million shs
GLUE Monte Rosa Therapeutics	$5.16 -1.9%	$4.52	$3.50 ▼ $12.40	$323.54M	1.41	1.09 million shs	237,425 shs
NTLA Intellia Therapeutics	$11.53 -5.2%	$9.06	$5.90 ▼ $28.18	$1.26B	2.21	3.04 million shs	3.73 million shs
PAHC Phibro Animal Health	$30.80 -1.1%	$24.79	$16.16 ▼ $31.80	$1.25B	0.75	220,581 shs	330,261 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	-5.65%	+5.39%	+24.15%	+67.08%	+43.21%
GLUE Monte Rosa Therapeutics	-1.90%	+2.28%	+2.18%	+22.27%	+32.31%
NTLA Intellia Therapeutics	-5.18%	+7.61%	+37.75%	+55.60%	-50.19%
PAHC Phibro Animal Health	-1.09%	+10.04%	+26.28%	+76.00%	+87.92%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABCL AbCellera Biologics	2.4439 of 5 stars	3.5	1.0	0.0	0.0	3.2	3.3	0.0
GLUE Monte Rosa Therapeutics	2.0442 of 5 stars	3.3	1.0	0.0	0.0	2.7	1.7	0.6
NTLA Intellia Therapeutics	4.3821 of 5 stars	4.3	1.0	0.0	4.7	1.6	2.5	0.6
PAHC Phibro Animal Health	4.0532 of 5 stars	0.9	4.0	2.5	1.1	3.1	3.3	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABCL AbCellera Biologics	3.00	Buy	$7.50	87.03% Upside
GLUE Monte Rosa Therapeutics	2.67	Moderate Buy	$15.33	197.16% Upside
NTLA Intellia Therapeutics	2.65	Moderate Buy	$33.37	189.41% Upside
PAHC Phibro Animal Health	1.83	Reduce	$24.40	-20.78% Downside

Current Analyst Ratings Breakdown

Latest GLUE, ABCL, PAHC, and NTLA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/7/2025	ABCL AbCellera Biologics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/7/2025	ABCL AbCellera Biologics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$5.00
7/7/2025	PAHC Phibro Animal Health	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$25.00 ➝ $35.00
6/25/2025	PAHC Phibro Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$21.00 ➝ $26.00
6/16/2025	NTLA Intellia Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral	$7.00
6/16/2025	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
6/16/2025	PAHC Phibro Animal Health	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
6/16/2025	PAHC Phibro Animal Health	BNP Paribas Exane Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Neutral	$24.00
6/3/2025	NTLA Intellia Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$74.00 ➝ $54.00
5/29/2025	NTLA Intellia Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral	$10.00 ➝ $7.00
5/29/2025	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00

(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABCL AbCellera Biologics	$28.83M	41.51	N/A	N/A	$3.58 per share	1.12
GLUE Monte Rosa Therapeutics	$75.62M	4.20	N/A	N/A	$3.63 per share	1.42
NTLA Intellia Therapeutics	$57.88M	20.63	N/A	N/A	$8.56 per share	1.35
PAHC Phibro Animal Health	$1.19B	1.05	$2.09 per share	14.73	$6.34 per share	4.86

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABCL AbCellera Biologics	-$162.86M	-$0.56	N/A	N/A	N/A	-737.56%	-15.98%	-12.38%	8/7/2025 (Estimated)
GLUE Monte Rosa Therapeutics	-$72.70M	$0.08	64.51	N/A	N/A	3.86%	2.65%	1.65%	8/14/2025 (Estimated)
NTLA Intellia Therapeutics	-$519.02M	-$5.23	N/A	N/A	N/A	-1,154.10%	-56.06%	-44.25%	8/14/2025 (Estimated)
PAHC Phibro Animal Health	$2.42M	$0.78	39.49	14.67	0.52	2.68%	30.51%	6.89%	8/27/2025 (Estimated)

Latest GLUE, ABCL, PAHC, and NTLA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	ABCL AbCellera Biologics	-$0.17	N/A	N/A	N/A	$7.55 million	N/A
5/8/2025	Q1 2025	ABCL AbCellera Biologics	-$0.17	-$0.15	+$0.02	-$0.15	$7.12 million	$4.24 million
5/8/2025	Q1 2025	GLUE Monte Rosa Therapeutics	-$0.24	$0.57	+$0.81	$0.57	$13.57 million	$84.93 million
5/8/2025	Q1 2025	NTLA Intellia Therapeutics	-$1.26	-$1.10	+$0.16	-$1.10	$11.39 million	$16.63 million
5/7/2025	Q3 2025	PAHC Phibro Animal Health	$0.52	$0.63	+$0.11	$0.51	$352.41 million	$347.80 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABCL AbCellera Biologics	N/A	N/A	N/A	N/A	N/A
GLUE Monte Rosa Therapeutics	N/A	N/A	N/A	N/A	N/A
NTLA Intellia Therapeutics	N/A	N/A	N/A	N/A	N/A
PAHC Phibro Animal Health	$0.48	1.56%	N/A	61.54%	N/A

Latest GLUE, ABCL, PAHC, and NTLA Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/6/2025	PAHC Phibro Animal Health	quarterly	$0.12	2.52%	6/4/2025	6/4/2025	6/25/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABCL AbCellera Biologics	N/A	10.15	10.15
GLUE Monte Rosa Therapeutics	N/A	5.61	5.61
NTLA Intellia Therapeutics	N/A	4.90	4.90
PAHC Phibro Animal Health	2.67	2.91	1.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABCL AbCellera Biologics	61.42%
GLUE Monte Rosa Therapeutics	79.96%
NTLA Intellia Therapeutics	88.77%
PAHC Phibro Animal Health	99.34%

Insider Ownership

Company	Insider Ownership
ABCL AbCellera Biologics	28.90%
GLUE Monte Rosa Therapeutics	6.90%
NTLA Intellia Therapeutics	3.10%
PAHC Phibro Animal Health	50.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABCL AbCellera Biologics	500	298.42 million	212.18 million	Optionable
GLUE Monte Rosa Therapeutics	90	61.51 million	57.27 million	Optionable
NTLA Intellia Therapeutics	600	103.58 million	100.37 million	Optionable
PAHC Phibro Animal Health	1,940	40.53 million	20.24 million	Optionable

GLUE, ABCL, PAHC, and NTLA Headlines

Recent News About These Companies

Phibro Animal Health (PAHC) is a Great Momentum Stock: Should ... - Nasdaq

1 hour ago | nasdaq.com

PAHC Phibro Animal Health Corporation - Seeking Alpha

1 hour ago | seekingalpha.com

Phibro Animal Health (PAHC) is a Great Momentum Stock: Should You Buy?

July 11 at 11:47 AM | msn.com

Phibro Animal Health Corporation (NASDAQ:PAHC) Given Consensus Rating of "Reduce" by Analysts

July 11 at 4:20 AM | marketbeat.com

Best Growth Stocks to Buy for July 10th

July 10 at 9:11 AM | zacks.com

Invest in 4 Winning Stocks With Proven Relative Price Power

July 9 at 9:26 AM | zacks.com

Phibro Animal Health (NASDAQ:PAHC) Upgraded by JPMorgan Chase & Co. to "Overweight" Rating

July 9 at 2:55 AM | americanbankingnews.com

JP Morgan Upgrades Phibro Animal Health (PAHC)

July 8, 2025 | msn.com

Phibro (PAHC) Soars 6.8%: Is Further Upside Left in the Stock?

July 8, 2025 | msn.com

Best Growth Stocks to Buy for July 8th

July 8, 2025 | zacks.com

Phibro Animal Health (NASDAQ:PAHC) Sets New 12-Month High - Still a Buy?

July 8, 2025 | marketbeat.com

Overlooked Stock: PAHC Taps 4-Year High

July 7, 2025 | youtube.comY

Phibro's Feed Play Pays Off: JPMorgan Upgrades On Zoetis Deal Boost

July 7, 2025 | benzinga.com

Phibro Animal Health stock surges after JPMorgan upgrade to Overweight

July 7, 2025 | in.investing.com

Phibro Animal Health (NASDAQ:PAHC) Shares Gap Up - Still a Buy?

July 7, 2025 | marketbeat.com

Phibro Animal Health (NASDAQ:PAHC) Upgraded to Overweight at JPMorgan Chase & Co.

July 7, 2025 | marketbeat.com

Phibro Animal Health Corporation (PAHC) Hit a 52 Week High, Can the Run Continue? - Nasdaq

July 3, 2025 | nasdaq.com

Phibro Animal Health Corporation (PAHC) - Investing.com

July 3, 2025 | investing.com

Phibro Animal Health Stock Up 52.8% in a Year: What's Driving the Rise? - Nasdaq

July 3, 2025 | nasdaq.com

Phibro Animal Health Corporation (PAHC) Hit a 52 Week High, Can the Run Continue?

July 2, 2025 | zacks.com

Phibro Animal Health (NASDAQ:PAHC) Hits New 1-Year High - Here's What Happened

July 2, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLUE, ABCL, PAHC, and NTLA Company Descriptions

AbCellera Biologics NASDAQ:ABCL

$4.01 -0.24 (-5.65%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$4.07 +0.06 (+1.50%)

As of 07/11/2025 07:59 PM Eastern

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Monte Rosa Therapeutics NASDAQ:GLUE

$5.16 -0.10 (-1.90%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$5.20 +0.04 (+0.68%)

As of 07/11/2025 06:29 PM Eastern

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Intellia Therapeutics NASDAQ:NTLA

$11.53 -0.63 (-5.18%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$11.51 -0.02 (-0.21%)

As of 07/11/2025 07:55 PM Eastern

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Phibro Animal Health NASDAQ:PAHC

$30.80 -0.34 (-1.09%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$30.78 -0.03 (-0.08%)

As of 07/11/2025 05:25 PM Eastern

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time